Loading stock data…
NXGL
$0.58-0.00 (-0.46%)
Market OpenUpdated 1:28 PM EDT
NEXGEL, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
NEXGEL, Inc. in the Healthcare sector is trading at $0.58 with a market capitalization of $5M. Wall Street consensus targets $2.00 (1 analysts), implying a +245.2% move over the next 12 months. The stock is currently near its 52-week low of $0.48, remaining 61.4% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +245.2% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $2.65M↓ | $2.80M↓ | $2.93M↑ | $2.88M↑ | $2.81M |
| Gross Profit | $1.06M↑ | $819,000↓ | $1.24M↓ | $1.26M↑ | $1.19M |
| Operating Income | -$958,000↑ | -$1.21M↓ | -$725,000↓ | -$636,000↑ | -$777,000 |
| Net Income | -$927,000↑ | -$970,000↓ | -$653,000↑ | -$665,000↑ | -$712,000 |
Peer Comparison
JNJUNHPFE
Fundamentals
NEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels for wound care, medical diagnostics, transdermal drug delivery, and cosmetics in the United States. It operates through two segments: Nex...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$5.29M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-80.50%
Volume
Today's trading volume
16,154
Recent News
Nexgel (NXGL) Q1 2026 Earnings Transcript
On today's call, I would like to provide an overview of our first quarter 20 financial results and bring everyone up to speed on the progress we have made on the integration of the acquisition we recently closed in mid April. The business year-over-year was relatively flat, with sales from Silly George coming in lower, which were partially offset by revenue growth in both contract manufacturing and our MEDAGEL brand. During the quarter, the increase in our SG&A was due primarily to costs incurred relating to the acquisition of our BioNX division and the KISS Nail Products legal case which has since been settled.
NEXGEL, Inc. Q4 2025 Earnings Call Summary
Moby summary of NEXGEL, Inc.'s Q4 2025 earnings call
NexGel Inc (NXGL) Q4 2025 Earnings Call Highlights: Strong Revenue Growth Amid Operational ...
NexGel Inc (NXGL) reports robust sales and successful product launches, but faces increased costs and supply chain delays.
NEXGEL, Inc.'s (NASDAQ:NXGL) Shift From Loss To Profit
NEXGEL, Inc. ( NASDAQ:NXGL ) is possibly approaching a major achievement in its business, so we would like to shine...
NexGel Inc (NXGL) Q3 2025 Earnings Call Highlights: Progress Towards Profitability Amidst ...
NexGel Inc (NXGL) reports steady revenue growth and improved margins, while logistical delays and revised guidance pose challenges.